Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: A novel histamine H4 receptor antagonist

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 21, 2011, Pages 6596-6602

  Mowbray, Charles E ^a   Bell, Andrew S ^a   Clarke, Nicholas P ^a   Collins, Michelle ^a   Jones, Rhys M ^a   Lane, Charlotte A L ^a   Liu, Wai L ^a   Newman, Sandra D ^a   Paradowski, Michael ^a   Schenck, Emanuel J ^a   Selby, Mathew D ^a   Swain, Nigel A ^a   Williams, David H ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Biomarker; Clinical candidate; GPCR antagonist; H4 receptor; Histamine; PF 3893787; Toxicity studies

Indexed keywords

1 (5 CHLORO 2 INDOLYLCARBONYL) 4 METHYLPIPERAZINE; AMIDE; AMIDINE; HISTAMINE H4 RECEPTOR; HISTAMINE H4 RECEPTOR ANTAGONIST; N 4 (CYCLOPROPYLMETHYL) 6 [3 (METHYLAMINO)PYRROLIDIN 1 YL]PYRIDIMDINE 2,4 DIAMINE; PF 3893787; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DOG; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; RAT;

RATTUS;

EID: 80054781260     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.07.125     Document Type: Article

References (31)

1. Dunford, P. J.; Thurmond, R. L. Prog. Respir. Res 2010, 39, 187;
2. Bhatt, H. G.; Agrawal, Y. K.; Raval, H. G.; Manna, K.; Desai, P. R. Mini-Rev. Med. Chem. 2010, 10, 1293;
3. Engelhardt, H.; Smits, R. A.; Leurs, R.; Haaksma, E.; de Esch, I. J. P. Curr. Opin. Drug Discovery Dev. 2009, 12, 628.
4. Bunnage, M. E. Nat. Chem. Biol. 2011, 7, 335.
5. Jablonowski, J. A.; Grice, C. A.; Chai, W.; Dvorak, C. A.; Venable, J. D.; Kwok, A. K.; Ly, K. S.; Wei, J.; Baker, S. M.; Desai, P. J.; Jiang, W.; Wilson, S. J.; Thurmond, R. L.; Karlsson, L.; Edwards, J. P.; Lovenberg, T. W.; Carruthers, N. I. J. Med. Chem. 2003, 46, 3957.
6. Zhang, M.; Thurmond, R. L.; Dunford, P. J. Pharmacol. Ther. 2007, 113, 594.
7. Park, B. K.; Boobis, A.; Clarke, S.; Goldring, C. E. P.; Jones, D.; Kenna, J. G.; Lambert, C.; Laverty, H. G.; Naisbitt, D. J.; Nelson, S.; Nicoll-Griffith, D. A.; Obach, S.; Routledge, P.; Smith, D. A.; Tweedie, D. J.; Vermeulen, N.; Williams, D. P.; Wilson, I. D.; Baillie, T. A. Nat. Rev. Drug Disc. 2011, 10, 292.
8. Hopkins, A. L.; Groom, C. R.; Alex, A. Drug Discovery Today 2004, 9, 430.
9. We first presented the work described in this paper at the Gordon Research Conference on Medicinal Chemistry at Colby-Sawyer College, New London, NH, USA, August 12, 2010 in a presentation by Charles E. Mowbray titled: 'The Discovery and Evaluation of PF-3893787: A Novel Histamine H4 Receptor Antagonist'. The compounds described in that presentation and this letter were first disclosed in patent applications
10. 'Preparation of substituted 2,4- diaminopyrimidines as histamine H4 receptor ligands' Bell, A. S.; Lane, C. A. L.; Mowbray, C. E.; Selby, M. D.; Swain, N. A.; Williams, D. H. World Patent Application WO 2007072163
11. Preparation of octahydropyrrolo[3,4- c]pyrrole derivatives as histamine H4 receptor ligands' ane, C. A. L.; Price, D. A. U.S. Patent Application US 2006111416. Since then a group from Johnson & Johnson has published an in vitro structure activity study 'Triamino pyrimidines and pyridines as histamine H4 receptor modulators'
12. Meduna, S. P.; Savall, B. M; Cai, H.; Edwards, J. P.; Thurmond, R. L.; McGovern, P. M.; Bioorg. Med. Chem. Lett. 2011, 21, 3113.
13. Binding Ki values were determined by displacement of specific [3H]-histamine binding from membranes prepared from HEK-293 cells stably expressing the full length human H4R. Detailed experimental details are provided in Ref. 7a.
14. Functional Ki values for antagonists were determined using HEK-293 cells expressing the full-length human H4R and a CRE-b-lactamase reporter gene. Antagonists reversed histamine inhibition of forskolin-stimulated cAMP. Detailed experimental details are provided in Ref. 7a.
15. Other authors have independently explored the benzimidazole template: (a) Terzioglu, N.; van Rijn, R. M.; Bakker, R. A.; De Esch, I. J. P.; Leurs, R. Bioorg. Med. Chem. Lett. 2004, 14, 5251;
16. Venable, J. D.; Cai, H.; Chai, W.; Dvorak, C. A.; Grice, C. A.; Jablonowski, J. A.; Shah, C. R.; Kwok, A. K.; Ly, K. S.; Pio, B.; Wei, J.; Desai, P. J.; Jiang, W.; Nguyen, S.; Ling, P.; Wilson, S. J.; Dunford, P. J.; Thurmond, R. L.; Lovenberg, T. W.; Karlsson, L.; Carruthers, N. I.; Edwards, J. P. J. Med. Chem. 2005, 48, 8289.
17. We have recently published further synthetic chemistry in this series: 'Synthesis of A Novel Octahydro Pyrrolo[3,4-c]Pyrrole Cyclic Amidine via 1,3- Dipolar Cycloaddition of Azomethine Ylides' Paradowski, M.; Lane, C. AL.; Peakman, T. Synlett 2011, 1543.
18. (a) Van de Waterbeemd, H.; Smith, D. A.; Beaumont, K.; Walker, D. J. Med. Chem. 2001, 44, 1313;
19. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Adv. Drug Delivery Rev. 2001, 46, 3.
20. Price, D. A.; Blagg, J.; Jones, L.; Greene, N.; Wager, T. Expert Opin. Drug Metab. Toxicol. 2009, 5, 921;
21. Ploemen, J.-P. H. T. M.; Kelder, J.; Hafmans, T.; van de Sandt, H.; van Burgsteden, J. A.; Salemink, P. J. M.; van Esch, E. Exp. Toxicol. Pathol. 2004, 55, 347.
22. Grimwood, S.; Hartig, P. R. Pharmacol. Ther. 2009, 122, 281.
23. A 7-day oral in vivo toleration study in rats achieved up to a free Cmax 197x projected human Cmin (10-15 nM) which represents 240x rat binding Ki. There was no evidence of toxicity. Similarly a 7-day oral in vivo toleration study in dogs achieved up to a free Cmax 187x the projected human Cmin (10-15 nM) which represents 1.7x dog binding Ki. There was no evidence of toxicity.
24. Barnard, R.; Barnard, A.; Salmon, G.; Liu, W.; Sreckovic, S. Cytometry 2008, 73A, 299.
25. Liu, C.; Wilson, S. J.; Kuei, C.; Lovenberg, T. W. J. Pharmacol. Exp. Ther. 2001, 299, 121.
26. Lim, H. D.; de Graaf, C.; Jiang, W.; Sadek, P.; McGovern, P. M.; Istyastono, E. P.; Bakker, R. A.; de Esch, I. J. P.; Thurmond, R. L.; Leurs, R. Mol. Pharmacol. 2010, 77, 734.
27. Seifert, R.; Schneider, E. H.; Dove, S.; Brunskole, I.; Neumann, D.; Strasser, A.; Buschauer, A. Mol. Pharmacol. 2011, 79, 631.
28. H4 receptor agonists have recently been reviewed: Igel, P.; Dove, S.; Buschauer, A. Bioorg. Med. Chem. Lett. 2010, 20, 7191;
29. 'Molecular Determinants of Selective Agonist and Antagonist Binding to the Histamine H4 Receptor' have also recently been described: Istyastano, E. P.; de Graaf, C.; de Esch, I. J. P.; Leurs, R. Curr. Top. Med. Chem. 2011, 11, 661.
30. A recent report described benzimidazole oximes as H4R agonists: Yu, F.; Wolin, R. L.; Wei, J.; Desai, P. J.; McGovern, P. M.; Dunford, P. J.; Karlsson, L.; Thurmond, R. L. J. Recept. Ligand Channel Res. 2010, 3, 37.
31. Liu, W. L. Inflamm. Res. 2010, 59, S339.